NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
ZME Science on MSN
New Injectable Therapy Helped Paralyzed Mice Walk and It Just Passed a Major Test on Human Cells
In a petri dish at Northwestern University, researchers grow organoids modeled on the human spinal cord: simplified, lab-made ...
Morning Overview on MSN
New nasal vaccine shields lungs for months from viruses, bacteria, and allergens
Stanford Medicine researchers have developed an experimental nasal vaccine that shielded mouse lungs for at least three months against a striking range of respiratory threats, from SARS-CoV-2 and ...
Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results